文献速递肾癌与肾肿瘤

主动监测与肾切除术治疗T1a期小肾肿块的匹配分析

A Matched Analysis of Active Surveillance Versus Nephrectomy for T1a Small Renal Masses.
PubMed 文献 · Eur Urol Oncol · 2023-02-04

本研究基于2000-2020年机构数据库,匹配年龄55-75岁、≤4cm T1a期小肾肿块患者,比较主动监测与肾切除术的生存结局。匹配后每组110例,5年总生存率肾切除组96% vs 主动监测组95%(HR 0.83,95%CI 0.13-5.32;p=0.8),无事件生存率分别为93%和96%(HR 1.88,95%CI 0.35-10.15;p=0.5),均无显著差异。

要点

  • 匹配后主动监测组5年总生存率95%,肾切除组96%,无显著差异。
  • 5年无事件生存率主动监测组96%,肾切除组93%,无显著差异。
  • 作者认为结果支持主动监测在较年轻、较健康患者中的安全性。

核心结论

  • 在年龄和总体健康状况匹配的小肾肿块患者中,主动监测的5年总生存率和无事件生存率与肾切除术无显著差异,结果支持主动监测在较年轻、较健康患者中的安全性。

研究设计与样本

  • 研究为匹配分析,基于机构数据库(2000-2020年)识别年龄55-75岁、≤4cm T1a期小肾肿块患者,按年龄、性别、ECOG体能状态、活检状态和组织学精确匹配主动监测与肾切除亚组。
  • 共纳入377例患者(主动监测205例,肾切除172例),匹配后每组110例,平均年龄64岁,77%为男性,75% ECOG评分为0。

主要发现

  • 匹配后每组47%接受活检,以透明细胞组织学为主。
  • 预测5年总生存率肾切除组96% vs 主动监测组95%(HR 0.83,95%CI 0.13-5.32;p=0.8)。
  • 5年无事件生存率肾切除组93% vs 主动监测组96%(HR 1.88,95%CI 0.35-10.15;p=0.5)。

临床怎么用

  • 作者认为结果支持主动监测在较年轻、较健康的小肾肿块患者中的安全性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While patients with a small renal mass (SRM) on active surveillance (AS) experience excellent metastasis-free survival (MFS) and cancer-specific survival (CSS), differences in overall survival (OS) observed may be explained by selection of older/comorbid patients for AS. Few studies have evaluated AS versus primary intervention in clinically balanced groups. We identified patients aged 55-75 yr with an SRM (≤4 cm, T1a) in our institutional database (2000-2020). Patients from AS and nephrectomy subgroups were matched exactly for age, sex, Eastern Cooperative Oncology Group (ECOG) performance status, biopsy status, and histology. The primary outcomes were OS and an event-free survival (EFS) composite that included OS, CSS, MFS, progression, or systemic therapy, which we tested in Cox proportional-hazards models. We identified 377 patients (205 AS, 172 nephrectomy). The cohort was balanced after matching (n = 110; mean age 64 yr, 77% male, and 75% ECOG score 0). In each arm, 47% were biopsied (predominantly clear-cell histology). The predicted 5-yr OS was 96% for the nephrectomy group and 95% for the AS group (hazard ratio for nephrectomy vs AS [HR] 0.83, 95% confidence interval [CI] 0.13-5.32; p = 0.8), with corresponding 5-yr EFS rates of 93% and 96% (HR 1.88, 95% CI 0.35-10.15; p = 0.5). Among SRM cases well matched for age and overall health status, we observed higher 5-yr OS and EFS rates for AS than previously reported; the rates were not significantly different from those after nephrectomy. The matched characteristics of our population are similar to those for treatment arms in contemporary cohorts and the results support the safety of AS in younger, healthier patients. PATIENT SUMMARY: While it has been shown that active surveillance for small kidney tumors is safe in older and more frail patients, its safety in younger, healthier patients has not been confirmed. We compared outcomes for patients aged 55-75 yr who were managed with surgery or active surveillance, and were similar in age and overall health. The probability of death after 5 years was low overall and not significantly different between the groups, suggesting that active surveillance is safe in routine clinical practice.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Cheung DC, Martin LJ, Komisarenko M, et al. A Matched Analysis of Active Surveillance Versus Nephrectomy for T1a Small Renal Masses. Eur Urol Oncol. 2023. PMID: 36746730. doi:10.1016/j.euo.2023.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。